NARMEDOS MEDICINA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 325,989 | 370,592 | 301,784 | 382,850 | 329,003 | 313,334 | 299,662 | 376,718 |
| Profit before tax | 51,146 | 59,318 | 119,461 | 24,402 | -31,752 | 4,514 | 15,848 | 29,184 |
| Net profit | 43,346 | 50,215 | 101,542 | 20,604 | -31,752 | 4,278 | 15,135 | 27,006 |
| Equity | 476,592 | 526,807 | 628,349 | 648,953 | 617,201 | 521,479 | 536,614 | 458,444 |
| Liabilities | 30,116 | 32,175 | 42,376 | 32,490 | 25,210 | 128,788 | 40,594 | 151,221 |
| Non-current assets | 324,800 | 302,850 | 312,466 | 303,653 | 276,011 | 224,220 | 206,801 | 161,216 |
| Current assets | 179,500 | 254,503 | 357,783 | 377,545 | 365,369 | 425,379 | 369,893 | 447,563 |
| Total assets | 504,300 | 557,353 | 670,249 | 681,198 | 641,380 | 649,599 | 576,694 | 608,779 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 26,603 | 47,430 | 39,675 |
| Social insurance contributions | - | - | - | - | - | 38,170 | 36,231 | 42,512 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +23.7% | +13.7% | -18.6% | +26.9% | -14.1% | -4.8% | -4.4% | +25.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 8.6% | 9.0% | 15.1% | 3.0% | -5.0% | 0.7% | 2.6% | 4.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 9.1% | 9.5% | 16.2% | 3.2% | -5.1% | 0.8% | 2.8% | 5.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 13.3% | 13.5% | 33.6% | 5.4% | -9.7% | 1.4% | 5.1% | 7.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 15.7% | 16.0% | 39.6% | 6.4% | -9.7% | 1.4% | 5.3% | 7.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.2 | 0.1 | 0.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 20,374 | 23,655 | 21,055 | 26,403 | 21,226 | 20,324 | 19,867 | 27,734 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
NARMEDOS MEDICINA - Social security debts
The company had no debts to Sodra
NARMEDOS MEDICINA - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-05-17 | 2025-05-20 | 4.0 |
| 2025-02-20 | 2025-02-27 | 15.7 |
| 2025-01-17 | 2025-01-31 | 15.7 |
| 2025-01-15 | 2025-01-16 | 365.67 |
| 2024-11-18 | 2024-11-23 | 25.78 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
NARMEDOS MEDICINA, UAB (code 125386774) is a Private Limited Liability Company operating in medical specialists activities. In 2025, the company generated revenue of €376.7K, up 25.7% year on year and 20.2% over two years. Net profit rose to €27.0K, after €15.1K in 2024 and €4.3K in 2023, showing a clear improvement in profitability. The 2025 net profit margin was 7.2%, compared with 5.1% in 2024 and 1.4% in 2023. Balance sheet size remained moderate, with total assets of €608.8K, equity of €458.4K and liabilities of €151.2K at the end of 2025. The equity ratio stood at 75.3%, while debt-to-equity was 0.33, indicating a relatively solid capital structure. Asset turnover was 0.62x, ROE was 5.9% and ROA was 4.4%. Revenue per employee was €29.0K and profit per employee was €2.1K. After a dip in revenue in 2024, the business returned to growth in 2025, with stronger earnings and a higher margin.